Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 31, 2016

View Archived Issues

Fostamatinib meets primary endpoint in the first study from the FIT phase III clinical program

NIAID awards grant to Hawaii Biotech for chikungunya virus vaccine research

FDA approves Afluria Quadrivalent influenza vaccine for people 18 years of age and older

FDA approves biosimilar etanercept Erelzi

Oblato's disufenton sodium receives FDA orphan drug designation

OPKO Health completes Transition Therapeutics acquisition

Merck Patent discloses NUDT1 inhibitors

Nanjing Gator Meditech and Jilin University patent PI3Kdelta inhibitors

Ningbo Wenda Pharmaceutical Technology develops EGFR inhibitors

FDA accepts NDA for edaravone in ALS

Yissum Research Development reports anticancer agents

Ariad completes rolling NDA submission for brigatinib

Sunshine Lake Pharma describes FXR agonists

Nymox's fexapotide shows clinically meaningful benefits in BPH

rAAV6-INT41 intrabody therapy shows promise in vivo for Huntington's disease

Debiopharm invests in start-up diagnostics company GenePOC

Merck KGaA discovers potent and selective inhibitors of the kinase GCN2

FDA accepts BLA for CSL-830

GlaxoSmithKline tests novel antimalarial quinazolindiones

ONO Pharmaceutical develops GABA(A) alpha-5 negative allosteric modulators

FDA responts to Oragenic's request for type C meeting

Valeant will commercialize Contrave in Canada under an agreement with Orexigen

DNA methylation-based assay significantly improves diagnosis of cancer of unknown primary

Kamada reports positive results on inhaled alpha-1 antitrypsin phase II trial

Arbutus Biopharma terminates exclusive license agreement with Kuros Biosciences

Novel desmin mutation causes left-dominant arrhythmogenic cardiomyopathy

FDA grants orphan drug designation to Genentech's etrolizumab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...